Ligand Pharm Cmn (LGND) 106.38 $LGND Intec Pharma

New Post Public Reply Private Reply Replies (0) Message Board

Sep 1, 2016 at 3:05 PM

Ligand Pharm Cmn (LGND) 106.38 $LGND

Intec Pharma Reports First Half 2016 Financial Results
BusinessWire - Thu Sep 01, 5:00AM CDT
Intec Pharma Ltd. (Nasdaq: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill(TM) platform technology, reports financial results for the three and six months ended June 30, 2016.
NTEC: 6.25 (+0.21), LGND: 106.38 (+3.07)

Ligand Pharmaceuticals (LGND) Is in Oversold Territory: What's Next?
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 8:34AM CDT
Ligand Pharmaceuticals Incorporated (LGND) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
LGND: 106.38 (+3.07)

Ligand Pharmaceuticals is Now Oversold (LGND)
MarketNewsVideo.com - Wed Aug 17, 11:03AM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
LGND: 106.38 (+3.07)

Results from Phase 1 Trials with Ligand's LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism
BusinessWire - Mon Aug 15, 8:00AM CDT
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announces that results from two Phase 1 clinical trials with LGD-6972, the company's investigational glucagon receptor antagonist, were published online in the August issue of the journal Diabetes, Obesity and Metabolism. The article is available here.
LGND: 106.38 (+3.07)

Zacks.com featured highlights: Ligand Pharmaceuticals, Ormat Technologies, Activision Blizzard, Boise Cascade and Ubiquiti Networks
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 8:30AM CDT
Zacks.com featured highlights: Ligand Pharmaceuticals, Ormat Technologies, Activision Blizzard, Boise Cascade and Ubiquiti Networks
BCC: 26.03 (-0.21), ATVI: 42.12 (+0.75), ORA: 48.58 (+0.18), UBNT: 51.96 (+0.56), LGND: 106.38 (+3.07)

5 Stocks to Play Momentum the Driehaus Way
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 8:53AM CDT
Momentum strategies that have the potential to offer healthy returns have always been the on radar of investors with a high risk appetite.
BCC: 26.03 (-0.21), ATVI: 42.12 (+0.75), ORA: 48.58 (+0.18), UBNT: 51.96 (+0.56), LGND: 106.38 (+3.07)

Ligand Pharmaceuticals Falls 1.77% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Aug 09, 2:54PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $115.00 to a high of $117.00. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $117.15 on volume of 315,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LGND: 106.38 (+3.07)

Inovio (INO) Q2 Loss in Line with Estimates, Revenues Top
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 8:41AM CDT
Inovio (INO) reported a loss of 26 cents per share in the second quarter of 2016, in line with the Zacks Consensus Estimate.
INO: 9.08 (-0.09), AZN: 32.63 (-0.18), LGND: 106.38 (+3.07), CORT: 5.31 (-0.02)

Endocyte (ECYT) Q2 Loss Wider than Expected (Revised)
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 4:31AM CDT
Endocyte (ECYT) reported a second-quarter 2016 loss of 33 cents per share, wider than the Zacks Consensus Estimate of a loss of 26 cents.
ECYT: 2.95 (-0.03), GERN: 2.71 (+0.02), LGND: 106.38 (+3.07), CORT: 5.31 (-0.02)

SmarTrend Watching for Potential Rebound in Shares of Ligand Pharmaceuticals After 6.49% Loss
Comtex SmarTrend(R) - Fri Aug 05, 1:23PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $119.16 to a high of $130.06. Yesterday, the shares fell 6.5%, which took the trading range below the 3-day low of $131.02 on volume of 871,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LGND: 106.38 (+3.07)

Ligand (LGND) Q2 Earnings Decline Y/Y, Maintains View
Arpita Dutt - Zacks Investment Research - Fri Aug 05, 5:48AM CDT
Ligand (LGND) maintained its 2016 outlook for both earnings and revenues.
GILD: 77.20 (-1.18), GERN: 2.71 (+0.02), LGND: 106.38 (+3.07), ANIK: 47.82 (+0.58)

Ligand (LGND) Beats Q2 Earnings, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:41AM CDT
Ligand (LGND) maintained its track record by surpassing earnings expectations yet again.
LGND: 106.38 (+3.07)

Ligand Reports Second Quarter 2016 Financial Results
BusinessWire - Thu Aug 04, 7:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2016, and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 9:00 a.m. Eastern time to discuss this announcement and answer questions.
LGND: 106.38 (+3.07)

Ligand (LGND) Q2 Earnings: What's in Store for the Stock?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 6:18AM CDT
Our proven model does not conclusively show that Ligand (LGND) is likely to beat earnings estimates this quarter.
RPTP: 7.26 (-0.19), TECH: 106.84 (+1.49), LGND: 106.38 (+3.07), XLRN: 30.12 (+0.11)

Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals
BusinessWire - Fri Jul 29, 7:30AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of a license agreement for three programs utilizing Ligand's LTP (Liver Targeting Prodrug) technology with Nucorion Pharmaceuticals, Inc., a venture-funded biotechnology company focused on developing anti-cancer and anti-viral agents initially directed to China.
LGND: 106.38 (+3.07)

7 Profitable Medical Stocks Ranked as Buys Now
Arpita Dutt - Zacks Investment Research - Tue Jun 21, 2:52PM CDT
It may be tough going for medical stocks but these 7 companies sporting a favorable Zacks Rank are poised to generate profits this year.
ZTS: 50.87 (-0.23), JNJ: 118.90 (-0.44), PFE: 34.66 (-0.14), LGND: 106.38 (+3.07), BMY: 56.78 (-0.61), AMPH: 18.70 (-0.30)

7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.53 (+0.09), RTRX: 16.27 (+0.25), AVEO: 0.92 (-0.01), SNSS: 0.84 (+0.03), LGND: 106.38 (+3.07), BIND: 0.78 (-0.09), ACOR: 24.21 (+0.13)

SmarTrend Watching for Potential Pullback in Shares of Ligand Pharmaceuticals After 1.08% Gain
Comtex SmarTrend(R) - Wed Jun 15, 3:13PM CDT
Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $115.62 to a high of $117.18. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $116.07 on volume of 107,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LGND: 106.38 (+3.07)

Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 4.58 (-0.04), BIIB: 305.80 (+0.17), IDRA: 1.87 (-0.04), RTRX: 16.27 (+0.25), LGND: 106.38 (+3.07), ACOR: 24.21 (+0.13)

Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 43.08 (+0.25), OMED: 10.16 (+0.17), LGND: 106.38 (+3.07), ANIK: 47.82 (+0.58)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Employment Law Suit Hits ABC: Alleged Wage Violations

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

JOYEE N01 Debuts Globally with First 2,000 Deliveries

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

D-Wave Quantum Hit with Securities Fraud Lawsuit

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

KINGRVER Boosts RV Comfort with New Water Heater Lineup

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....